Clinical Trials Logo

Carcinoma, Endometrioid clinical trials

View clinical trials related to Carcinoma, Endometrioid.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05390021 Withdrawn - Clinical trials for Cytoreductive Surgery

PET/MRI in Endometrial Cancer

Start date: March 30, 2024
Phase: N/A
Study type: Interventional

This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial cancer. The name of the intervention involved in this study is: Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)

NCT ID: NCT05295589 Withdrawn - Clinical trials for Recurrent Platinum-Resistant Ovarian Carcinoma

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial compares copanlisib and olaparib to standard of care chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous platinum-based chemotherapy (platinum resistant) and that has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib and olaparib may extend the time that the cancer does not progress compared to standard of care chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT04611139 Withdrawn - Endometrial Cancer Clinical Trials

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.

NCT ID: NCT04498520 Withdrawn - Clinical trials for Recurrent Ovarian Carcinoma

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Start date: March 31, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer. Abexinostat may prevent tumor cells from growing and multiplying and may kill tumor cells. Palbociclib may prevent or slow the growth of tumor cells when used with other anti-hormonal therapy. Estrogen can cause the growth of breast and gynecologic tumor cells. Fulvestrant may help fight breast or gynecologic cancer by blocking the use of estrogen by the tumor cells. Giving abexinostat, palbociclib, and fulvestrant may work better in treating patients with breast or gynecologic cancer.

NCT ID: NCT03677024 Withdrawn - Clinical trials for Endometrial Endometrioid Adenocarcinoma

Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas

Start date: February 6, 2020
Phase: N/A
Study type: Interventional

To evaluate the efficacy of sentinel lymph node policy in patients with intermediate-risk endometrial carcinomas

NCT ID: NCT01732432 Withdrawn - Endometriosis Clinical Trials

Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)

EAOC
Start date: October 2012
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma. All histopathological records since 1980 with these diagnoses (endometriosis, clear cell and endometrioid ovarian carcinoma) will be reviewed. Cancer registry data will be assessed to investigate differences in survival of women with endometriosis-associated ovarian carcinomas and those ovarian carcinoma patients without previous diagnosis of endometriosis.

NCT ID: NCT01492920 Withdrawn - Pain Clinical Trials

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Start date: April 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer undergoing chemotherapy. Acetyl-L-carnitine hydrochloride may prevent or lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine hydrochloride is more effective compared to a placebo in preventing peripheral neuropathy caused by chemotherapy.

NCT ID: NCT00173407 Withdrawn - Ovarian Cancer Clinical Trials

PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion

Start date: January 2006
Phase: N/A
Study type: Interventional

We have identified insulin-like growth factor binding protein (IGFBP)-3 as an invasion suppressor gene in ovarian endometrioid carcinoma, and showed association with lower cancer migration, invasion and metastasis. Recently, a novel model of ovarian EC formation from endometriosis was reported, and PTEN was found to be a major protein involved. Inactivation of PTEN has been reported in some ovarian EC tumors and methylation was suggested as one of the major epigenetic changes. This tumorigenesis model has lots of similarity to our established invasion model. Therefore, we plan to study the important of PTEN expression in ovarian EC and if inactivation of PTEN and IFGBP-3 is through methylation. Furthermore, by studying the signal transduction pathways using PTEN and IGFBP-3 transfection, we plan to study the mutual interaction between PTEN and IGFBP-3 on the suppression of tumor invasion in ovarian EC.